/other/Diamyd_Medical_AB_publ-logo.png){kind=logo}
Diamyd Medical AB (publ)
A clinical-stage company developing precision therapies for autoimmune diabetes.
DMYD | ST
Overview
Corporate Details
- ISIN(s):
- SE0005162872 (+5 more)
- LEI:
- 5493003NP2HNQDEKB804
- Country:
- Sweden
- Address:
- BOX 7349, 103 90 STOCKHOLM
- Website:
- https://www.diamyd.com/
- Sector:
- Manufacturing
Description
Diamyd Medical is a clinical-stage company developing precision medicine therapies for the prevention and treatment of autoimmune diabetes, primarily Type 1 Diabetes. Its lead candidate, Diamyd®, is an antigen-specific immunotherapy based on the GAD65 protein. The therapy is designed to preserve the body's remaining insulin-producing capacity by re-educating the immune system to tolerate insulin-producing cells, thereby halting their autoimmune destruction. Diamyd® is being evaluated in late-stage clinical development, including the pivotal Phase III trial DIAGNODE-3, which utilizes a proprietary method of intralymphatic administration. The company is also establishing its own manufacturing facility for the GAD65 active pharmaceutical ingredient.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Diamyd Medical AB (publ) filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Diamyd Medical AB (publ)
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Diamyd Medical AB (publ) via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
